Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 533

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

Open access
Narayan, Vivek, Barber-Rotenberg, Julie S., Jung, In-Young, Lacey, Simon F., Rech, Andrew J., Davis, Megan M., Hwang, Wei-Ting, Lal, Priti, Carpenter, Erica L., Maude, Shannon L., Plesa, Gabriela, Vapiwala, Neha, Chew, Anne, Moniak, Michael, Sebro, Ronnie A., Farwell, Michael D., Marshall, Amy, Gilmore, Joan, Lledo, Lester, Dengel, Karen, Church, Sarah E., Hether, Tyler D., Xu, Jun, Gohil, Mercy, Buckingham, Thomas H., Yee, Stephanie S., Gonzalez, Vanessa E., Kulikovskaya, Irina, Chen, Fang, Tian, Lifeng, Tien, Kyle, Gladney, Whitney, Nobles, Christopher L., Raymond, Hayley E., Prostate Cancer Cellular Therapy Program Investigators, Frazee, Diane, Truran, Mary, Veloso, Elizabeth, McConville, Holly, Aguedelo, Jonathan, Hower, Samantha, Ngo, Sophia, Jadlowsky, Julie, Melenhorst, J. Joseph, Roche, Aoife, Everett, John, Gupta, Minnal, Nazimuddin, Farzana, Bartoszek, Chelsie, Koterba, Natalka, Reynolds, Rachael, Ellington, Farris, Kloss, Christopher C., Lee, Jihyun, Zhao, Yangbing, Scholler, John, Riley, James L., Bailey, Christina, White, Andrew, Hudson, Briana, Chang, Pearl, Maus, Marcela V., Levine, Bruce L., Hexner, Elizabeth O., Siegel, Donald L., Bushman, Frederic D., June, Carl H., Fraietta, Joseph A., Haas, Naomi B.·2022·Nature Medicine
DOI 10.1038/s41591-022-01726-1
Open this paper in CoChat — free account

Abstract

Chimeric antigen receptor (CAR) T cells have demonstrated promising efficacy, particularly in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the immunosuppressive tumor microenvironment (TME), characterized by high levels of multiple inhibitory factors, including transforming growth factor (TGF)-β. We report results from an in-human phase 1 trial of castration-resistant, prostate cancer-directed CAR T cells armored with a dominant-negative TGF-β receptor (NCT03089203). Primary endpoints were safety and feasibility, while secondary objectives included assessment of CAR T cell distribution, bioactivity and disease response. All prespecified endpoints were met. Eighteen patients enrolled, and 13 subjects received therapy across four dose levels. Five of the 13 patients developed grade ≥2 cytokine release syndrome (CRS), including one patient who experienced a marked clonal CAR T cell expansion, >98% reduction in prostate-specific antigen (PSA) and death following grade 4 CRS with concurrent sepsis. Acute increases in inflammatory cytokines correlated with manageable high-grade CRS events. Three additional patients achieved a PSA reduction of ≥30%, with CAR T cell failure accompanied by upregulation of multiple TME-localized inhibitory molecules following adoptive cell transfer. CAR T cell kinetics revealed expansion in blood and tumor trafficking. Thus, clinical application of TGF-β-resistant CAR T cells is feasible and generally safe. Future studies should use superior multipronged approaches against the TME to improve outcomes. CAR T cells targeting PSMA and engineered to be resistant to immunosuppressive TGFβ signaling exhibit dose-dependent toxicity and expansion following infusion, with some transient antitumor activity, in patients with metastatic castration-resistant prostate cancer

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-01726-1

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 533

Metadata

Authors
Narayan, V., Barber-Rotenberg, J. S., Jung, I.-Y., Lacey, S. F., Rech, A. J., Davis, M. M., Hwang, W.-T., Lal, P., Carpenter, E. L., Maude, S. L., Plesa, G., Vapiwala, N., Chew, A., Moniak, M., Sebro, R. A., Farwell, M. D., Marshall, A., Gilmore, J., Lledo, L., Dengel, K., Church, S. E., Hether, T. D., Xu, J., Gohil, M., Buckingham, T. H., Yee, S. S., Gonzalez, V. E., Kulikovskaya, I., Chen, F., Tian, L., Tien, K., Gladney, W., Nobles, C. L., Raymond, H. E., Prostate Cancer Cellular Therapy Program Investigators, Frazee, D., Truran, M., Veloso, E., McConville, H., Aguedelo, J., Hower, S., Ngo, S., Jadlowsky, J., Melenhorst, J. J., Roche, A., Everett, J., Gupta, M., Nazimuddin, F., Bartoszek, C., Koterba, N., Reynolds, R., Ellington, F., Kloss, C. C., Lee, J., Zhao, Y., Scholler, J., Riley, J. L., Bailey, C., White, A., Hudson, B., Chang, P., Maus, M. V., Levine, B. L., Hexner, E. O., Siegel, D. L., Bushman, F. D., June, C. H., Fraietta, J. A., & Haas, N. B.
Venue
Nature Medicine
Publisher
Springer Science and Business Media LLC
Published
2022-03-21
Volume
28
Issue
4
Pages
724-734
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
DOI
10.1038/s41591-022-01726-1
OpenAlex
W4220882995
Cited by
533
References
15
FWCI
37.97
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. https://app.cochat.ai/papers/10.1038/s41591-022-01726-1
The paper
Narayan, V., Barber-Rotenberg, J. S., Jung, I.-Y., Lacey, S. F., Rech, A. J., Davis, M. M., Hwang, W.-T., Lal, P., Carpenter, E. L., Maude, S. L., Plesa, G., Vapiwala, N., Chew, A., Moniak, M., Sebro, R. A., Farwell, M. D., Marshall, A., Gilmore, J., Lledo, L., . . . Haas, N. B. (2022). PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nature Medicine. https://doi.org/10.1038/s41591-022-01726-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.